number: 1
title: Acquisition Agreement Section 1.1
author_name: Grant
month: Febuary
president_name: Grant
year: 2016
day: 25

Section 1.1 Acquired Assets . On the terms and subject to the conditions set forth in this Agreement and, subject to approval of the Bankruptcy Court, pursuant to Sections 105, 363 and 365 of the Bankruptcy Code, at the Closing, the Sellers shall sell, assign, transfer, convey and deliver to the Purchaser, and the Purchaser shall purchase and accept from the Sellers, free and clear of all Encumbrances other than Permitted Encumbrances, all right, title and interest of the Sellers in and to all rights, properties and assets of the Sellers related to theBusiness, wherever located, whether tangible or intangible, as the same shall exist on the Closing Date, other than the Excluded Assets (collectively, the “ Acquired Assets ”), including all right, title and interest of the Sellers in and to the Acquired Assets that are listed or described below:(a) the Interests;(b) other than as set forth in Section 1.2(m) , all accounts receivable that are owed or payable to any Seller;(c) all intercompany accounts receivable as to which any Seller or Non-Debtor Sub is an obligor or is otherwise responsible or liable and which are owed or payable to any Seller;(d) all credits, claims for refunds, deposits for the benefit of third parties and prepaid expenses (other than credits, refunds, deposits and prepaid amounts with respect to Taxes), except that Acquired Assets includes any such items with respect to any Taxes for Post-Closing Periods that relate to the Acquired Assets or the Assumed Liabilities, and any Taxes borne by Purchaser pursuant to Section 8.1(b) );(e) the Contracts listed, described or otherwise identified (by reference to counterparty, type and proposed cure amount) on Schedule 1.1(e) , as such schedule may be amended from time to time pursuant to Section 5.20 (such Contracts, the “ Assigned Contracts ”);(f) all rights and remedies under all warranties, representations and guarantees made by suppliers, manufacturers and contractors;(g) all inventory, finished goods, works in process, raw materials and packaging materials;(h) the real property leases listed, described or otherwise identified (by reference to counterparty, type and proposed cure amount) on Schedule 1.1(e) , as such schedule may be amended from time to time pursuant to Section 5.20 (such leases, the “ Assumed Leases ”);(i) all equipment, computers, furniture, furnishings, fixtures, office supplies, vehicles, tools, leasehold improvements and all other tangible personal property;(j) all (i) patents and patent applications, including provisionals, continuations, continuations-in-part, divisionals, substitutions, reissues, reexaminations and any extensions and supplementary protection certificates; (ii) trademarks, service marks, trade dress, trade names, logos, slogans, Internet domain names and other similar designations of source or origin, together with the goodwill symbolized by, and any registrations and applications for, the foregoing; (iii) copyrights and database rights, and any copyright registrations and applications; (iv) trade secrets, including trade secret rights in inventions, discoveries, know-how, proprietary processes, formulae, research and development information, clinical data, cell lines, manufacturing technology and data, marketing and sales information, customer lists and supplier lists; and (v) any other intellectual property rights recognized in any relevant jurisdiction (collectively, “ Intellectual Property ”), including such of the foregoing as are listed or described on Schedule 1.1(j) ;(k) all rights in computer software programs and information technology systems;(l) all rights under non-disclosure or confidentiality, invention and Intellectual Property assignment, non-compete or non-solicitation agreements for the benefit of the Sellers with current or former employees and agents of the Sellers or with third parties (in the case of rights under the Parent Confidentiality Agreements, solely to the extent provided in Section 5.15(a) );(m) the approval of the Biologics License Application from the FDA and the related Biologics License and, indirectly through the transfer of the Transferred Sub, the marketing authorization from the European Commission, with respect to the biologic Provenge;(n) other than as set forth in Section 1.2(e) , all Documents that are used in, held for use in or intended to be used in, or that arise out of the Business, including Documents relating to the biologic Provenge, services, marketing, advertising, promotional materials, Intellectual Property, personnel files for Transferred Employees and all files, customer files and documents, supplier lists, records literature and correspondence, whether or not physically located on any of the real property leased under any Assumed Leases;(o) to the extent transferable, all Permits and Environmental Permits and all pending applications therefor;(p) other than as set forth in Section 1.2(b) or Section 1.2(j) , to the extent transferable, all insurance policies and rights thereunder;(q) other than as set forth in Section 1.2(e) or Section 1.2(f) , all books and records, including, without limitation, all correspondence, documents, and records in connection with the Biologics License and the marketing authorization from the European Commission with respect to the biologic Provenge;(r) all goodwill and other intangible assets associated with the Business, the Acquired Assets and the Assumed Liabilities;(s) all rights, claims or causes of action of any Seller to the extent related to the Business, the Acquired Assets or the Assumed Liabilities (for avoidance of doubt, excluding all rights, claims or causes of action of any Seller set forth in Sections 1.2(g) , 1.2(h) , 1.2(i) and 1.2(j) ); and(t) the Benefit Plans listed or described on Schedule 1.1(t) (the “ Assumed Benefit Plans ”).EXCEPT AS SPECIFICALLY AND EXPRESSLY SET FORTH IN ARTICLE III , OR ANY ANCILLARY DOCUMENT DELIVERED BY ANY SELLER PURSUANT TO THIS AGREEMENT (I) THE SELLERS MAKE NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AT LAW OR IN EQUITY, RELATING TO THE BUSINESS, THE ACQUIRED ASSETS OR THE ASSUMED LIABILITIES, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO VALUE, MERCHANTABILITY, FITNESSFOR A PARTICULAR PURPOSE OR FOR ORDINARY PURPOSES, OR ANY OTHER MATTER, (II) THE SELLERS MAKE NO, AND HEREBY DISCLAIM ANY, OTHER REPRESENTATION OR WARRANTY REGARDING THE BUSINESS, THE ACQUIRED ASSETS OR THE ASSUMED LIABILITIES, AND (III) THE BUSINESS, THE ACQUIRED ASSETS AND THE ASSUMED LIABILITIES ARE CONVEYED ON AN “AS IS, WHERE IS” BASIS AS OF THE CLOSING, AND THE PURCHASER SHALL RELY UPON THEIR OWN EXAMINATION THEREOF. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, THE SELLERS MAKE NO REPRESENTATION OR WARRANTY REGARDING ANY BUSINESS OTHER THAN THE BUSINESS, ANY ASSETS OTHER THAN THE ACQUIRED ASSETS OR ANY LIABILITIES OTHER THAN THE ASSUMED LIABILITIES, AND NONE SHALL BE IMPLIED AT LAW OR IN EQUITY.